Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 30 May 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 16 Dec 2016 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.